Gain (GANX) Climbs 7.14% on June 21

Equities Staff  |

Gain Therapeutics Inc (NASDAQ: GANX) has risen $0.26 (7.14%) and sits at $3.90, as of 11:48:04 est on June 21.

124,418 shares have traded hands.

The Company rose 12.00% over the last 5 days and shares advanced 31.88% over the last 30 days.

Gain is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on Gain visit the company profile.

About Gain Therapeutics Inc

Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

To get more information on Gain Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Gain Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?

Market Movers

Sponsored Financial Content